A novel inhibitor of respiratory syncytial virus isolated from ethnobotanicals

被引:25
作者
Ojwang, JO
Wang, YH
Wyde, PR
Fischer, NH
Schuehly, W
Appleman, JR
Hinds, S
Shimasaki, CD
机构
[1] Zymetx Inc, Oklahoma City, OK 73104 USA
[2] Univ Mississippi, Dept Pharmacognosy, University, MS 38677 USA
[3] Univ Mississippi, Nat Ctr Nat Prod Res, RIPS, University, MS 38677 USA
[4] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA
[5] InterGenet Inc, Oklahoma City, OK 73104 USA
关键词
inhibitors; antivirals; respiratory syncytial virus; natural product; ethnobotanicals;
D O I
10.1016/j.antiviral.2005.09.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel low molecular weight compound, CJ 4-16-4, isolated from ethnobotanicals using bioassay-guided fractionation, was found to be a potent inhibitor of respiratory syncytial virus (RSV) in vitro and in vivo. In vitro, a very low micromolar efficacious dose was obtained against at least four of subtype A (RSV-Long, RSV A2, and RSV A6 57754) and one of subtype B (Washington) RSV strains without seeing any significant cytotoxicity to Hep-2, MDCK or Vero cell lines. The drug inhibits growth of RSV in Hep-2 cells maintained in tissue culture at a very low concentration (similar to 0.07 mu M) with cell toxicity > 400 mu M (TI > 5880). In a cotton rat model of RSV infection, the drug was able to reduce viral titers by similar to 1 log at dose 12.5 and 25 mg/kg/day, and by > 2 log at 100mg/kg/day. This antiviral activity was specific as influenza A and B and herpes simplex I and 2 viruses were not inhibited. The results obtained indicate that CJ 4-16-4 warrants clinical development. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 37 条
[1]   NATURAL PRODUCT DRUG DISCOVERY AND DEVELOPMENT - NEW PERSPECTIVES ON INTERNATIONAL COLLABORATION [J].
BAKER, JT ;
BORRIS, RP ;
CARTE, B ;
CORDELL, GA ;
SOEJARTO, DD ;
CRAGG, GM ;
GUPTA, MP ;
IWU, MM ;
MADULID, DR ;
TYLER, VE .
JOURNAL OF NATURAL PRODUCTS, 1995, 58 (09) :1325-1357
[2]  
Baset P, 1996, BIOL PHARM BULL, V19, P1479, DOI 10.1248/bpb.19.1479
[3]   EXPOSURE OF HEALTH-CARE WORKERS TO RIBAVIRIN DURING THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS-INFECTIONS [J].
BRADLEY, JS ;
CONNOR, JD ;
COMPOGIANNIS, LS ;
EIGER, LL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (04) :668-670
[4]  
CHANOCK RM, 1990, FIELDS VIROLOGY, P1045
[5]   Orally active fusion inhibitor of respiratory syncytial virus [J].
Cianci, C ;
Yu, KL ;
Combrink, K ;
Sin, N ;
Pearce, B ;
Wang, A ;
Civiello, R ;
Voss, S ;
Luo, GX ;
Kadow, K ;
Genovesi, EV ;
Venables, B ;
Gulgeze, H ;
Trehan, A ;
James, J ;
Lamb, L ;
Medina, I ;
Roach, J ;
Yang, Z ;
Zadjura, L ;
Colonno, R ;
Clark, J ;
Meanwell, N ;
Krystal, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :413-422
[6]   THE APPLICATION OF VACUUM LIQUID-CHROMATOGRAPHY TO THE SEPARATION OF TERPENE MIXTURES [J].
COLL, JC ;
BOWDEN, BF .
JOURNAL OF NATURAL PRODUCTS, 1986, 49 (05) :934-936
[7]  
Collins P.L., 1996, FIELDS VIROLOGY, V3, P1313
[8]  
Crews P., 1998, Organic Structure Analysis
[9]  
CUI X, 2002, Patent No. 20020111382
[10]   Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults [J].
Dowell, SF ;
Anderson, LJ ;
Gary, HE ;
Erdman, DD ;
Plouffe, JF ;
File, TM ;
Marston, BJ ;
Breiman, RF .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (03) :456-462